Immunovant, Inc.IMVTEarnings & Financial Report
Nasdaq
IMVT Q4 2024 Key Financial Metrics
Revenue
$8.4M
Gross Profit
N/A
Operating Profit
$-75.1M
Net Profit
$-75.3M
Gross Margin
N/A
Operating Margin
-896.2%
Net Margin
-899.0%
YoY Growth
140.7%
EPS
$-0.50
Financial Flow
Immunovant, Inc. Q4 2024 Financial Summary
Immunovant, Inc. reported revenue of $8.4M for Q4 2024, with a net profit of $-75.3M (-899.0% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $8.4M |
|---|---|
| Net Profit | $-75.3M |
| Gross Margin | N/A |
| Operating Margin | -896.2% |
| Report Period | Q4 2024 |
Immunovant, Inc. Annual Revenue by Year
Immunovant, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $24.9M).
| Year | Annual Revenue |
|---|---|
| 2024 | $24.9M |
| 2023 | $7.6M |
Income Statement
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $1.2M | $2.9M | $3.5M | $4.1M | $3.6M | $8.9M | $8.4M |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | 209.5% | 203.4% | 140.7% |
Balance Sheet
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $458.7M | $428.1M | $456.2M | $405.8M | $351.2M | $292.1M | $711.4M | $666.4M |
| Liabilities | $22.2M | $32.4M | $41.6M | $43.3M | $51.4M | $40.3M | $32.1M | $48.6M |
| Equity | $436.5M | $395.7M | $414.7M | $362.5M | $299.9M | $251.8M | $679.3M | $617.8M |
Cash Flow
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-65.8M | $-20.2M | $-46.4M | $-55.8M | $-47.4M | $-60.1M | $-47.1M | $-59.7M |